55 results
8-K
EX-10.1
BGNE
BeiGene Ltd
20 Mar 24
Departure of Directors or Certain Officers
4:10pm
”) of BeiGene, Ltd. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high
8-K
EX-10.1
pbaahoj0
29 Mar 23
Other Events
4:03pm
8-K
EX-10.1
zn7qv8e3kkh32m5zz6
22 Feb 22
BRUKINSA was granted approval by the European Commission for the treatment of Waldenström’s macroglobulinemia in November 2021
4:10pm
8-K
EX-1.1
uif8ri
6 Dec 21
Entry into a Material Definitive Agreement
4:10pm
8-K
EX-99.3
0aebq8141 lgcokx
11 Jun 21
Other Events
4:23pm
8-K
EX-10.1
tu7x775qlnvlkf
8 Apr 21
BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics
4:15pm
8-K
EX-99.1
o4qiw6gaqgwbwva7l5
17 Feb 21
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug
4:10pm
8-K
EX-99.1
vq9gdv4 f6nx
11 Jan 21
Regulation FD Disclosure
7:01am
8-K
EX-1.1
f0b3484
2 Dec 20
BeiGene Launches Proposed Public Offering by Selling Shareholders
5:17pm